Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making

This covers those essential market changing initiatives which make tomorrow’s drug market different from today’s. Successful deal making has accurate valuation at its heart. Anything that impacts a drugs ability to achieve in the future a fair and profitable market price impacts its value today. The current market is more challenging than ever before. Payer-driven price negotiation for reimbursement, and cost-containment programmes to control prescribing, both challenge the traditional pricing model the industry has used to generate valuable R&D resource to further the search for innovation and better disease control.

The adoption of new ways in assessing value offers industry and payers opportunity to find common ground. Economic arguments will predominate in decision making and should be modelled early in a product’s life and be both visible and valuable to deal makers.

This report covers:

Current deal making environment

Assessment of traditional risk models used

Analysis of current P&R market

Impact of biotech drugs on the market

Orphan drug concerns and pressures

Review of patent protection for paediatric drugs

Pharmacoeconomics

Benchmarking

Valuation components and future drivers of value

Hard Copy Published July 2007
Table of Contents
Price: $3,395.00 / GBP1,697.50